

FINANCIAL HIGHLIGHTS

Positive trading performance helped by resurgent Companion Animals demand further strengthens financial position in pursuit of Group's growth strategy.

Revenue

£74.0m ↑ 5.0%




Underlying* EBITDA

£13.5m ↑ 11.3%




Underlying* EPS

12.0p ↑ 13.2%



Net debt


£5.3m ↓ £8.3m



Strategic and operational highlights

- Daxocox approved in EU and UK and launched successfully across all markets, generating £1.2m in second half sales
- 8.3% increase in revenues generated by top 40 brands through continuing focus on optimisation of portfolio
- Sandra Single joins Senior Executive Team in new role of Strategic Product and Portfolio Director
- Roll out of Group-wide leadership development programme
- Continuing investment in people with focus on sales and marketing excellence
- Pipeline strengthened post year end through early-stage licensing and collaboration deal with Orthros Medical for innovative antibody therapy

* A reconciliation of underlying to reported results can be found on page 24.



CONTENTS

Business Overview

Highlights	01
Our Group at a glance	02
Our geographic presence	03
Chairman's Statement	04
Our marketplace	06

Strategic Report

Our strategy	10
Our Key Performance Indicators	14
Business Model	16
Chief Executive Officer's Review	18
Chief Financial Officer's Review	22
Our principal risks	27
Our stakeholders	34
Sustainability	38

Our Governance

Board of Directors	42
Corporate Governance Statement	46
Corporate Governance Report	49
Audit and Risk Committee Report	56
Remuneration and Nomination Committee Report	60
Directors' Remuneration Report	62
Directors' Report	66
Statement of Directors' Responsibilities	70

Our Financials

Independent Auditors' Report	72
Consolidated Income Statement	80
Consolidated Statement of Comprehensive Income	81
Consolidated Statement of Financial Position	82
Consolidated Statement of Changes in Equity	83
Consolidated Cash Flow Statement	84
Notes to the Consolidated Financial Statements	86
Company Statement of Financial Position	127
Company Statement of Changes in Equity	128
Company Cash Flow Statement	129
Notes to Financial Statements	130
Advisers	IBC